Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study

Rheumatology

Volumn 49, Issue 2, 2010, Pages 271-280

  Daoussis, Dimitrios ^a   Liossis, Stamatis Nick C ^a   Tsamandas, Athanassios C ^a   Kalogeropoulou, Christina ^a   Kazantzi, Alexandra ^a   Sirinian, Chaido ^a   Karampetsou, Maria ^a   Yiannopoulos, Georgios ^a   Andonopoulos, Andrew P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

B cells; Fibrosis; Interstitial lung disease; Rituximab; Scleroderma; Systemic sclerosis

Indexed keywords

BOSENTAN; CARBON MONOXIDE; COLLAGEN; CYCLOPHOSPHAMIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; FUNCTIONAL DISEASE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BIOPSY; CELL ADHESION MOLECULES; COLLAGEN; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE DEPLETION; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SKIN; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 77950443096     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep093     Document Type: Article

References (45)

1. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
2. Tashkin DP, Elashoff R, Clements PJ et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34.
3. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebocontrolled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
4. Yiannopoulos G, Pastromas V, Antonopoulos I et al. Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007; 27:357-61.
5. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45: 1005-8.
6. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology 2007; 46:442-5.
7. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE. Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology 2006;45:1572.
8. Fujimoto M, Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005;17:746-51.
9. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004;41: 1123-33.
10. Asano N, Fujimoto M, Yazawa N et al. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004; 165:641-50.
11. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50:1918-27.
12. Whitfield ML, Finlay DR, Murray JI et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319-24.
13. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56:3167-8.
14. Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954-66.
15. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapyrefractory chronic graft-versus-host disease. Blood 2004; 104:2603-6.
16. Carella AM, Biasco S, Nati S, Congiu A, Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease. Leuk Lymphoma 2007;48: 623-4.
17. Cutler C, Miklos D, Kim HT et al. Rituximab for steroidrefractory chronic graft-versus-host disease. Blood 2006; 108:756-62.
18. Okamoto M, Okano A, Akamatsu S et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172-3.
19. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood 2005; 105:4885-91.
20. Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007;20:349-60.
21. Perruche S, Marandin A, Kleinclauss F et al. Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graftversus- host disease occurrence. Transplantation 2006;81: 573-82.
22. Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San Miguel J. Chronic graft-versus-host disease: pathogenesis and clinical management. Drugs 2006;66:1041-57.
23. Nelson JL, Furst DE, Maloney S et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998;351:559-62.
24. Murata H, Nakauchi H, Sumida T. Microchimerism in Japanese women patients with systemic sclerosis. Lancet 1999;354:220.
25. Smith VP, Van Praet JT, Vandooren BR et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. Advance Access published December 22, 2008, doi: 0:ard.2008.095463v1.
26. Lafyatis R, Kissin E, York M et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578-83.
27. Bosello S, De Santis M, Lama G et al. Clinical improvement in systemic slerosis patients treated with anti-CD20. Arthritis Rheum Sup 2007;56:494.
28. Lombardi S, Quartuccio L, Franzolini N et al. Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis. Arthritis Rheum Sup 2008;58: S822-3.
29. McGonagle D, Tan AL, Madden J et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008;47: 552-3.
30. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
31. Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991;18:1520-8.
32. Valentini G, D'Angelo S, Della RA, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5.
33. Czirjak L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66:966-9.
34. Rangan GK, Tesch GH. Quantification of renal pathology by image analysis. Nephrology 2007;12:553-8.
35. Scopa CD, Vagianos C, Kardamakis D, Kourelis TG, Kalofonos HP, Tsamandas AC. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 2001;9:329-34.
36. Khanna D, Furst DE, Clements PJ et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40.
37. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4: 27-31.
38. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993;153:1337-42.
39. Nash RA, McSweeney PA, Crofford LJ et al. Highdose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388-96.
40. Wollheim FA. Is rituximab a potential new therapy in systemic sclerosis?: New evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J Clin Rheumatol 2004;10:155.
41. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
42. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13.
43. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123: 66-73.
44. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006;2: 679-85.
45. Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigendriven T cell disease? Arthritis Rheum 2004;50:1721-33.